The FDA has accepted a second investigational new drug (IND) application under Evotec and Bristol Myers Squibb’s strategic protein degradation partnership, with the candidate expected to enter Phase I trials in 2027.

AdobeStock_1012127840

Many proteins remain difficult to target using conventional small-molecule therapies. Molecular glue degraders (MGDs) offer a promising alternative, enabling the selective degradation of disease-relevant proteins, including those traditionally considered undruggable.

Evotec and Bristol Myers Squibb (BMS) have received a second IND acceptance from the US Food and Drug Administration (FDA) for a candidate developed through their strategic partnership in molecular glue degraders.

The investigational candidate is a cereblon E3 ligase modulator (CELMoD) and is expected to enter a Phase I clinical trial in 2027. It follows the first candidate from the collaboration, which entered Phase I development in March 2026 for advanced clear cell renal cell carcinoma.

Established in 2018 and expanded in 2022, the partnership combines Evotec’s multi-omics screening, AI-supported data analytics and drug design capabilities with BMS’s CELMoD agent library. The collaboration aims to develop molecular glue degraders against high-value targets in oncology and other indications.

CELMoDs work by inducing interactions between cereblon (CRBN), an E3 ubiquitin ligase, and target proteins, triggering their ubiquitination and subsequent degradation, potentially expanding the range of proteins that can be targeted therapeutically.

Dr Joanna Holbrook, Chief Scientific Officer at Evotec, said: “The progression of a second molecular glue candidate to IND acceptance demonstrates the repeatability and productivity of our discovery platform.”

Topics